ARTICLE | Clinical News
CancerVax completes enrollment in melanoma Phase III
September 22, 2004 7:00 AM UTC
CNVX completed enrollment of 1,118 stage III melanoma patients in a Phase III trial of its Canvaxin immunotherapy. The compound also is in an ongoing Phase III trial in patients with stage IV melanoma...